VITROS® B•R•A•H•M•S PCT
The Power of B•R•A•H•M•S with the Difference that only VITROS can Deliver

Sepsis

- Life-threatening clinical condition caused by the body’s extreme response to infection
- When unrecognized and untreated, sepsis leads to systemic inflammation, tissue damage and ultimately organ failure and death
- Affects more than 30 million people with six million deaths around the world each year

Procalcitonin and Sepsis

- Early diagnosis of systemic bacterial infections
- Effective monitoring of sepsis patients
- Safe antibiotic therapy guidance

TRUST IN RESULTS FOR LABORATORIES:

<table>
<thead>
<tr>
<th>Reliability:</th>
<th>Accuracy:</th>
<th>Efficiency:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fulfill more requests from difficult draws with small sample volume</td>
<td>Trust your results through a quantification of endogenous interferences hemolysis, icterus and turbidity</td>
<td>Maximize efficiency with long calibration intervals</td>
</tr>
</tbody>
</table>

30μL | 56 days |

CONFIDENCE IN DECISIONS FOR CLINICIANS:

- Early diagnosis of severe bacterial infections and sepsis
- Therapeutic guidance for starting and safely stopping antibiotic treatment
- Excellent analytical correlation and clinical concordance to B•R•A•H•M•S method

Procalcitonin is the best biomarker for early bacterial infection diagnosis and antibiotic stewardship

VITROS B•R•A•H•M•S PCT assay delivers:

- High analytical sensitivity and specificity
- Results that are ready to be delivered to clinicians with 96.5% First Pass Yield (without user intervention)
- Analytical performance: LOD at 0.007 ng/mL, LOQ (20% CV, observed) at 0.013 ng/mL
- Fast turnaround time: 24 minutes to first result
- VITROS B•R•A•H•M•S PCT Assay is the reliable solution
VITROS® B•R•A•H•M•S PCT

Excellent Analytical and Operational Performance

Measuring Range: 0.030-100 ng/mL (0.030-100 µg/L)
LOD: 0.007 ng/mL (0.007 µg/L)
LOQ (claimed): 0.030 ng/mL (0.030 µg/L)
LOQ (observed at 20% CV): 0.013 ng/mL (0.013 µg/L)

Precision at clinical decision points:
≤3.9% at 0.100 ng/mL
≤3.5% at 0.250 ng/mL
≤3.7% at 0.500 ng/mL
≤4.0% at 2.00 ng/mL
≤4.1% at >2.00 ng/mL

Calibration interval: 56 days

VITROS System to System correlation: within <3.7%
Not impacted by biotin interference

Excellent Analytical Correlation

Analytical correlation between VITROS B•R•A•H•M•S PCT and B•R•A•H•M•S PCT sensitive KRYPTOR

Slope = 1.06
Intercept = -0.010 ng/mL
r = 0.994

Excellent Clinical Concordance

Clinical concordance to B•R•A•H•M•S method at clinical decision points

<table>
<thead>
<tr>
<th>Concentration (ng/mL)</th>
<th>Concordance</th>
</tr>
</thead>
<tbody>
<tr>
<td>0.100</td>
<td>98.5%</td>
</tr>
<tr>
<td>0.250</td>
<td>98.0%</td>
</tr>
<tr>
<td>0.500</td>
<td>97.4%</td>
</tr>
<tr>
<td>2.00</td>
<td>97.8%</td>
</tr>
<tr>
<td>10.0</td>
<td>98.0%</td>
</tr>
</tbody>
</table>

INTENDED USE

The VITROS B•R•A•H•M•S PCT test is indicated as an aid to be used in conjunction with clinical evaluation for:
• The early detection and differential diagnosis of clinically relevant bacterial infections
• The assessment of the degree of severity and the prognosis of the outcome of systemic bacterial infection, sepsis, severe sepsis and septic shock
• Identifying patients that benefit from antibiotic treatment
• Monitoring of antibiotic therapy within the measuring range
• The assessment of successful antibiotic therapy in patients with suspected or confirmed bacterial infection

Indicated for use with the VITROS ECi/ECiQ/3600 Immunodiagnostic Systems and the VITROS 5600/XT 7600 Integrated Systems.

PRODUCT INFORMATION

<table>
<thead>
<tr>
<th>ITEM</th>
<th>CATALOG NO.</th>
</tr>
</thead>
<tbody>
<tr>
<td>VITROS Immunodiagnostic Products B•R•A•H•M•S PCT Reagent</td>
<td>690 5558</td>
</tr>
<tr>
<td>VITROS Immunodiagnostic Products B•R•A•H•M•S PCT Calibrator Pack</td>
<td>690 5559</td>
</tr>
<tr>
<td>VITROS Immunodiagnostic Products B•R•A•H•M•S PCT Controls Tri-Level</td>
<td>690 5560</td>
</tr>
</tbody>
</table>

References